Peng Katie 4

What Happened

• Katie Peng, a director of Adicet Bio, was granted 4,200 shares (reported as a derivative award) on 2026-06-21. The filing reports a $0 acquisition price for the award (transaction code A), reflecting a restricted stock award rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-21; Filing date: 2026-06-23 (filed within the standard Form 4 window).
• Shares granted: 4,200; reported price: $0 (derivative/award).
• Shares owned after transaction: not specified in this Form 4.
• Footnote: Shares vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to Peng’s continued board service.
• Transaction type: A = Award/Grant (not an open-market buy or sale).

Context

• Awards to directors are commonly part of compensation and do not necessarily signal a personal market view. This grant vests based on continued service/timing of the next annual meeting, so it functions as retention/compensation rather than an immediate investment move.